NEW YORK, November 9, 2020 — EVQLV’s founders are thrilled to (officially) announce that Richard Fox has joined our team as Chief Scientific Officer. Dr. Fox spent nearly two decades at the Fred Hutchinson Cancer Research Center. Within industry he led virology efforts for the HIV, Hepatitis C and coinfection franchises at Merck that included the commercial launch of Zepatier. Prior to embarking on his scientific career Dr. Fox had a distinguished career in the U.S. Special Forces. Richard is guiding the scientific strategy of the company and ensuring that the experiments we run to validate our technology are scientifically valuable, clinically relevant, and bring us to the clinic.